Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 May;31(5):444-50.
doi: 10.1097/AJP.0000000000000142.

Onset of analgesia and efficacy of ibuprofen sodium in postsurgical dental pain: a randomized, placebo-controlled study versus standard ibuprofen

Patrick Brain  1 , Rina Leyva, Geraldine Doyle, David Kellstein
Affiliations
Randomized Controlled Trial

Onset of analgesia and efficacy of ibuprofen sodium in postsurgical dental pain: a randomized, placebo-controlled study versus standard ibuprofen

Patrick Brain et al. Clin J Pain. 2015 May.

Abstract

Objectives: A novel, immediate-release tablet formulation of ibuprofen (IBU) sodium dihydrate, Advil Film Coated Tablets (IBUNa), has been developed that is absorbed faster than standard IBU tablets. The objective of the current study was to compare the efficacy and onset of analgesia of this new formulation with standard IBU tablets after a single dose.

Materials and methods: Patients (N=316) with at least moderate baseline postsurgical dental pain were randomized to 400 mg IBUNa, Advil (IBUAdv), Motrin (IBUMot), or placebo. Primary endpoints were time-weighted sum of pain relief (PR) and pain intensity differences over 8 hours (SPRID 0-8) and time to onset of meaningful pain relief (TMPR) measured by the double-stopwatch method.

Results: SPRID 0-8 was significantly greater for IBUNa and the other active treatments versus placebo (P<0.001). IBUNa had a significantly earlier TMPR versus placebo, pooled IBUAdv/IBUMot, and IBUMot (P<0.001 for all), and a marginally faster TMPR (P=0.075) versus IBUAdv. Results for secondary endpoints were similar. Adverse events were comparable across treatment groups, with gastrointestinal disorders being most frequently reported. Most adverse events were mild or moderate.

Discussion: This novel formulation of IBUNa provided superior overall PR compared with placebo and more rapid onset of analgesic effect compared with standard IBU tablets. Rapid PR is important in the treatment of acute pain, including dental pain, and this IBUNa formulation represents a new treatment option for rapid PR.

Trial registration: ClinicalTrials.gov NCT01098747.

PubMed Disclaimer

Conflict of interest statement

This study was sponsored by Pfizer Madison, NJ, USA. Financial support for medical editorial assistance was provided by Pfizer. R.L. and D.K. are employees of Pfizer Consumer Healthcare. G.D. is a former employee of Pfizer Consumer Healthcare. P.B. has received grant/research support from Jean Brown Research. P.B. declares no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Time to meaningful pain relief. Per protocol, the comparisons of pooled IBUAdv/IBUMot versus placebo and IBUAdv versus IBUMot were not performed. aP≤0.001 versus placebo. bP≤0.001 versus pooled IBUAdv/IBUMot. cP≤0.001 versus IBUMot. IBUAdv indicates Advil; IBUMot, Motrin; IBUNa, Advil Film Coated Tablets.
FIGURE 2
FIGURE 2
Pain relief rating combined with pain intensity difference (PRID) scores over time. Per protocol, the comparisons of pooled IBUAdv/IBUMot versus placebo and IBUAdv versus IBUMot were not performed. aP≤0.001 versus placebo. bP≤0.01 versus placebo. cP≤0.001 versus pooled IBUAdv/IBUMot. dP≤0.01 versus pooled IBUAdv/IBUMot. eP≤0.05 versus pooled IBUAdv/IBUMot. fP≤0.001 versus IBUAdv. gP≤0.01 versus IBUAdv. hP≤0.05 versus IBUAdv. iP≤0.001 versus IBUMot. jP≤0.01 versus IBUMot. kP≤0.05 versus IBUMot. lP≤0.05 versus IBUNa. IBUAdv indicates Advil; IBUMot, Motrin; IBUNa, Advil Film Coated Tablets; PRID, sum of pain intensity difference and pain relief rating.
FIGURE 3
FIGURE 3
Two-, 3-, 6-, and 8-hour summary efficacy measures. Per protocol, the comparisons of pooled IBUAdv/IBUMot versus placebo and IBUAdv versus IBUMot were not performed. aP≤0.001 versus placebo. bP≤0.01 versus pooled IBUAdv/IBUMot. cP≤0.05 versus IBUAdv. dP≤0.01 versus IBUMot. IBUAdv indicates Advil; IBUMot, Motrin; IBUNa, Advil Film Coated Tablets: ibuprofen sodium; SPID, time-weighted sum of pain intensity difference; SPRID, time-weighted sum of pain relief and pain intensity difference; TOTPAR, time-weighted sum of pain relief.
FIGURE 4
FIGURE 4
Global evaluation of study treatment. aP≤0.001 versus placebo. IBUAdv indicates Advil; IBUMot, Motrin; IBUNa, Advil Film Coated Tablets: ibuprofen sodium.
See this image and copyright information in PMC

References

    1. Advil [package insert]. Madison: Pfizer Consumer Healthcare, 2012.
    1. Motrin IB. [package insert]. Fort Washington, PA: McNeil Consumer Healthcare, a division of McNEIL-PPC Inc.; 2013.
    1. Braun RP, Lockhart EA, Bruno P. Delayed-onset muscle soreness (DOMS)—a new pain model to compare OTC analgesics [abstract 79]. Med Sci Sports Exerc. 1994;26suppl 5S14.
    1. Cooper SA, Schachtel BP, Goldman E, et al. Ibuprofen and acetaminophen in the relief of acute pain: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 1989;29:1026–1030. - PubMed
    1. Schachtel BP, Fillingim JM, Thoden WR, et al. Sore throat pain in the evaluation of mild analgesics. Clin Pharmacol Ther. 1988;44:704–711. - PubMed

Publication types

Associated data